These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20493446)

  • 1. [Hexaminolevulinate fluorescence cystoscopy in 2009].
    Jacqmin D; Bordier B; Guillotreau J
    Prog Urol; 2010 Mar; 20 Suppl 1():S50-3. PubMed ID: 20493446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.
    Witjes JA; Douglass J
    Nat Clin Pract Urol; 2007 Oct; 4(10):542-9. PubMed ID: 17921969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer--re-TURBT recurrence rates in a prospective, randomized study.
    Geavlete B; Jecu M; Multescu R; Georgescu D; Geavlete P
    Urology; 2010 Sep; 76(3):664-9. PubMed ID: 20627289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.
    Fradet Y; Grossman HB; Gomella L; Lerner S; Cookson M; Albala D; Droller MJ;
    J Urol; 2007 Jul; 178(1):68-73; discussion 73. PubMed ID: 17499291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
    Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
    Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blue light cystoscopy for detection and treatment of non-muscle invasive bladder cancer.
    Mark JR; Gelpi-Hammerschmidt F; Trabulsi EJ; Gomella LG
    Can J Urol; 2012 Apr; 19(2):6227-31. PubMed ID: 22512972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
    Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
    J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer.
    Stenzl A; Burger M; Fradet Y; Mynderse LA; Soloway MS; Witjes JA; Kriegmair M; Karl A; Shen Y; Grossman HB
    J Urol; 2010 Nov; 184(5):1907-13. PubMed ID: 20850152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing hexaminolevulinate HCl blue light cystoscopy: a nursing perspective.
    Calvaresi AE; Trabulsi EJ; Sonzogni M; Gomella LG; Lallas CD; Wachsmuth KS
    AORN J; 2014 Nov; 100(5):489-96; quiz 497-9. PubMed ID: 25443119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
    Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
    BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Initial experience in the diagnosis and treatment of superficial bladder tumors with Hexvix].
    Abascal Junquera JM; Hevia Suárez M; Abascal García JM; Estébanez C; Astudillo A; Abascal R
    Arch Esp Urol; 2008 May; 61(4):475-82; discussion 482-3. PubMed ID: 18592765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
    Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R
    Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
    Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
    Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation.
    Garfield SS; Gavaghan MB; Armstrong SO; Jones JS
    Can J Urol; 2013 Apr; 20(2):6682-9. PubMed ID: 23587507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.
    Grossman HB; Stenzl A; Fradet Y; Mynderse LA; Kriegmair M; Witjes JA; Soloway MS; Karl A; Burger M
    J Urol; 2012 Jul; 188(1):58-62. PubMed ID: 22583635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in fluorescence cystoscopy: do novel agents bring a benefit?
    Schmidbauer J; Marberger M
    Curr Opin Urol; 2007 Sep; 17(5):347-51. PubMed ID: 17762629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences?
    Karaolides T; Skolarikos A; Bourdoumis A; Konandreas A; Mygdalis V; Thanos A; Deliveliotis C
    Urology; 2012 Aug; 80(2):354-9. PubMed ID: 22857752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
    Neuzillet Y; Methorst C; Schneider M; Lebret T; Rouanne M; Radulescu C; Molinie V; Dreyfus JF; Pelcat V; Botto H
    Urol Oncol; 2014 Nov; 32(8):1135-40. PubMed ID: 25023786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.